Severe terminal ileitis induced by single-agent nivolumab administered every four weeks.
Constantin A DasanuSteven C PlaxeVarun GuptaIliana M PopescuMayumi GroverJuliana Alvarez-ArgotePublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
To our knowledge, this is the first report of terminal ileitis with nivolumab administered every four weeks. As postmarketing evaluation of nivolumab continues, similar side effects may be observed. Prompt diagnosis and steroid therapy in these cases are imperative to ensure a favorable outcome. Resuming immunotherapy once the adverse event has resolved appears to be a safe option.